A Medical Device Daily
SRU Biosystems (Woburn, Massachusetts) reported the receipt of several U.S. patents related to label-free biomolecular detection methods, saying that it now has 16 issued patents.
Owen Dempsey, president/CEO of SRU Biosystems, said, "SRU has been granted eight additional U.S. patents in the last few months that cover important aspects of our BIND technology, further strengthening our leading position in label-free detection for drug discovery and diagnostics."
The eight awarded patents are: No. 7,162,125 Optimized grating-based biosensor and substrate combination; No. 7,158,230 Method and apparatus for detecting biomolecular interactions; No. 7,153,702 Label-free methods for performing assays using a colorimetric resonant reflectance optical biosensor; No. 7,148,964 Method and apparatus for detecting biomolecular interactions; No. 7,142,296 Method and apparatus for detecting biomolecular interactions; No. 7,170,599 Method and instrument for detecting biomolecular interactions; No. 7,175,980 Method of making a plastic colorimetric resonant biosensor device with liquid handling capabilities; No. 7,197,198 Biosensor substrate structure for reducing the effect of optical interference.
BIND from SRU Biosystems enables label-free detection of biomolecular interactions. The commercially available system is comprised of the BIND Reader and 96- or 384-well microplate biosensors.
The BIND system takes advantage of a novel optical effect to provide very sensitive measurement of binding on the biosensor surface.
The biosensor incorporates a proprietary nanostructured optical grating, which is incorporated in microwell plates in industry standard formats.
SRU develops sensing and molecular biology technologies used to screen the interactions of large genomic, protein, peptide, or antibody libraries against a range of biochemical targets.